Should I buy or sell GSK stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares. View GSK analyst ratings or view top-rated stocks .

What is GSK's stock price target for 2024?

8 analysts have issued 12-month price targets for GSK's shares. Their GSK share price targets range from GBX 1,245 to GBX 2,000. On average, they expect the company's share price to reach GBX 1,566.36 in the next year. This suggests a possible upside of 9.5% from the stock's current price. View analysts price targets for GSK or view top-rated stocks among Wall Street analysts .

How have GSK shares performed in 2023?

GSK's stock was trading at GBX 1,437.60 on January 1st, 2023. Since then, GSK shares have decreased by 0.5% and is now trading at GBX 1,430.60. View the best growth stocks for 2023 here .

How were GSK's earnings last quarter?

GSK plc (LON:GSK) posted its quarterly earnings data on Wednesday, July, 29th. The company reported $56.90 earnings per share for the quarter. GSK had a trailing twelve-month return on equity of 61.26% and a net margin of 20.48%.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK announced a dividend on Wednesday, November 1st. Stockholders of record on Thursday, November 16th will be given a dividend of GBX 14 per share on Thursday, January 11th. This represents a dividend yield of 0.96%. The ex-dividend date is Thursday, November 16th. The official announcement can be viewed at this link . Read our dividend analysis for GSK .

Is GSK a good dividend stock?

GSK (LON:GSK) pays an annual dividend of GBX 56 per share and currently has a dividend yield of 4.00%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 3,783.78%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for GSK .

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN) , General Electric (GE) , Royal Dutch Shell (RDSB) , Vodafone Group Public (VOD) , Intel (INTC) , NVIDIA (NVDA) , Johnson & Johnson (JNJ) , AT&T (T) , Barclays (BARC) and Gilead Sciences (GILD) .

How do I buy shares of GSK?

Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

GSK Share Price, News & Analysis (LON:GSK)

GBX 1,430.50

-9.50 (-0.66%)

(As of 05:11 PM ET)

Compare

Today's Range: 1,426.80
▼
1,445.80
50-Day Range: 1,382
▼
1,521.40
52-Week Range: 1,302.60
▼
1,563.20

Volume: 4.36 million shs
Average Volume: 6.78 million shs
Market Capitalization: £58.65 billion

P/E Ratio: 966.55
Dividend Yield: 3.91%
Price Target: GBX 1,566.36

Stock Analysis Analyst Forecasts Chart Competitors Dividend Headlines Insider Trades Sustainability

GSK MarketRank™ Stock Analysis

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 9.5% Upside
GBX 1,566.36 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: -1.56
Upright™ Environmental Score
News Sentiment: 0.41
Based on 5 Articles This Week
Insider Trading: Acquiring Shares
£832,857 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

2.1

Analyst's Opinion

Consensus Rating
GSK has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 4 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 1,566.36, GSK has a forecasted upside of 9.5% from its current price of GBX 1,430.60.
Amount of Analyst Coverage
GSK has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

N/A

Short Interest

Short Interest
There is no current short interest data available for GSK.

1.7

Dividend Strength

Dividend Leadership
GSK is a leading dividend payer. It pays a dividend yield of 4.00%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
GSK does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of GSK is 3,783.78%. Payout ratios above 75% are not desirable because they may not be sustainable.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
GSK has received a 66.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "HIV medication", "Shingles vaccines", "Mouthwash", "Clinical research services for infectious diseases", "Clinical research services for cancer", and "Clinical research services for the respiratory system" products. See details.
Environmental Sustainability
The Environmental Impact score for GSK is -1.56.

1.3

News and Social Media Coverage

News Sentiment
GSK has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for GSK this week, compared to 5 articles on an average week.
Search Interest
Only 29 people have searched for GSK on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added GSK to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GSK insiders have bought more of their company's stock than they have sold. Specifically, they have bought £8,328.57 in company stock and sold GBX 0 in company stock.
Percentage Held by Insiders
Only 1.74% of the stock of GSK is held by insiders.
Percentage Held by Institutions
45.00% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of GSK is 966.62, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 120.28.
Price to Earnings Ratio vs. Sector
The P/E ratio of GSK is 966.62, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 130.76.
Price to Earnings Growth Ratio
GSK has a PEG Ratio of 0.94. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
GSK has a P/B Ratio of 4.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About GSK Stock (LON:GSK)

GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.

GSK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GSK Stock News Headlines

December 5, 2023 | theglobeandmail.com

GSK is a workplace where people can thrive

December 2, 2023 | finance.yahoo.com

Boasting A 52% Return On Equity, Is GSK plc (LON:GSK) A Top Quality Stock?

December 7, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 30, 2023 | msn.com

Competition and Optimism: GSK's CEO Walmsley Foresees Growth Despite Competition In RSV Vaccine Market

November 30, 2023 | msn.com

Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND

November 30, 2023 | reuters.com

GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year

November 30, 2023 | theguardian.com

Nigerians struggle to find medication after GSK pull-out

November 30, 2023 | americanbankingnews.com

Citigroup Reiterates Neutral Rating for GSK (LON:GSK)

December 7, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 28, 2023 | thetimes.co.uk

Trial success injects more confidence for GSK blood cancer treatment

November 27, 2023 | msn.com

GSK's Blenrep Combo Meets PFS Endpoint in Head-to-Head Study

November 27, 2023 | msn.com

GSK Frames A Comeback For Its Multiple Myeloma Drug Following Encouraging Phase 3 Data

November 27, 2023 | americanbankingnews.com

GSK (LON:GSK) Receives Buy Rating from Berenberg Bank

November 22, 2023 | msn.com

GSK makes first shipment of malaria vaccine to Africa: report

November 22, 2023 | msn.com

BRIEF-Gsk Will Start Phase III Trials Of Low Carbon Version Of Its Metered Dose Inhaler, Ventolin (Salbutamol) In 2024

November 21, 2023 | msn.com

GSK plans low-carbon asthma inhaler in bid to cut its greenhouse gas emissions

November 21, 2023 | msn.com

GSK plans low-carbon asthma inhaler in bid to cut emissions

November 21, 2023 | lse.co.uk

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

November 9, 2023 | forbes.com

GSK Buy Write Is Prescription For Quick Dividend

November 8, 2023 | msn.com

GSK: Shareholders express concerns over N1.274bn unclaimed dividends

November 3, 2023 | finance.yahoo.com

GSK outpaces Pfizer in RSV vaccine market

November 1, 2023 | morningstar.com

November 1, 2023 | uk.movies.yahoo.com

If I’d put £1,000 in GSK shares 1 year ago, here’s what I’d have today

November 1, 2023 | finance.yahoo.com

GSK (GSK) Q3 Earnings and Revenues Surpass Estimates

November 1, 2023 | msn.com

GSK to pay $1 billion for exclusive license to J&J's hepatitis B therapy

October 31, 2023 | msn.com

GSK Reports Earnings Wednesday. Here’s What to Expect.

October 31, 2023 | msn.com

UPDATE 2-GSK's cancer drug Jemperli meets overall survival goal in late-stage trial

See More Headlines

Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 7/29/2020
Ex-Dividend for 10/12 Dividend: 8/17/2023
Dividend Payable: 10/12/2023
Ex-Dividend for 1/11 Dividend: 11/16/2023
Today: 12/07/2023
Dividend Payable: 1/11/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Drug Manufacturers - General
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:GSK
CUSIP: N/A
CIK: N/A
Web: www.gsk.com
Phone: +44-20-80475000
Fax: N/A
Employees: 69,400
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: GBX 1,566.36
High Stock Price Target: GBX 2,000
Low Stock Price Target: GBX 1,245
Potential Upside/Downside: +8.8%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): GBX 1.48
Trailing P/E Ratio: 972.97
Forward P/E Ratio: 9.01
P/E Growth: 0.94
Net Income: £6.08 billion
Net Margins: 20.48%
Pretax Margin: N/A
Return on Equity: 61.26%
Return on Assets: 7.90%

Debt

Debt-to-Equity Ratio: 165.16
Current Ratio: 0.95
Quick Ratio: 0.73

Sales & Book Value

Annual Sales: £29.65 billion
Price / Sales: 1.99
Cash Flow: GBX 176.79 per share
Price / Cash Flow: 8.15
Book Value: GBX 324 per share
Price / Book: 4.44

Miscellaneous

Outstanding Shares: 4,100,000,000
Free Float: N/A
Market Cap: £59.04 billion
Optionable: Not Optionable
Beta: 0.29

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Ms. Emma Natasha Walmsley (Age 53)
CEO & Director
Comp: $4.79M
Ms. Julie Belita Brown (Age 61)
CFO & Executive Director
Ms. Shobie Ramakrishnan
Chief Digital & Technology Officer
Mr. Tony Wood
Chief Scientific Officer
Ms. Sarah Elton-Farr
Head of Investor Relations
Mr. James Ford
Senior VP & Group General Counsel of Legal & Compliance
Ms. Sally Jackson
Senior Vice President of Global Communications & CEO Office
Mr. David Simon Redfern BSc (Hons) (Age 57)
CA, President of Corporate Development
Ms. Diana Conrad
Chief People Officer
Mr. Philip C. Thomson
President of Global Affairs

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

Should I Buy GSK Stock? GSK Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of GSK was last updated on Monday, November 27, 2023 at 10:16 AM.

Pros

Here are some ways that investors could benefit from investing in GSK plc:

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines and specialty medicines to prevent and treat various diseases. This positions the company in a crucial and high-demand sector, offering potential for long-term growth.
GSK plc has a strong track record of innovation and a robust pipeline of new products. This indicates the potential for future revenue growth and expansion into new markets.
The company has a global presence and operates in multiple countries. This diversification helps mitigate risks associated with regional economic fluctuations and regulatory changes.
GSK plc has a history of paying dividends to its shareholders. This can provide a steady income stream for investors, especially those seeking income-oriented investments.
Recent developments and advancements in GSK plc's research and development efforts have shown promising results, indicating the potential for breakthrough treatments and therapies in the future.

Cons

Investors should be bearish about investing in GSK plc for these reasons:

GSK plc faces intense competition in the pharmaceutical industry. This competition can impact market share and pricing power, potentially affecting the company's profitability.
The company's financial performance may be influenced by factors such as changes in healthcare policies, regulatory approvals, and patent expirations. These external factors can introduce uncertainties and impact the company's revenue and profitability.
GSK plc has experienced challenges in the past related to legal and regulatory issues. These issues can result in reputational damage and financial penalties, which may negatively impact the company's stock performance.
The stock price of GSK plc is subject to market volatility and fluctuations. Investors should carefully consider their risk tolerance and investment horizon before investing in the company.
Investing in the pharmaceutical industry carries inherent risks, including the potential for clinical trial failures, regulatory hurdles, and market uncertainties. Investors should conduct thorough research and analysis before making investment decisions.

GSK Stock Analysis - Frequently Asked Questions

Should I buy or sell GSK stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings or view top-rated stocks.
What is GSK's stock price target for 2024?: 8 analysts have issued 12-month price targets for GSK's shares. Their GSK share price targets range from GBX 1,245 to GBX 2,000. On average, they expect the company's share price to reach GBX 1,566.36 in the next year. This suggests a possible upside of 9.5% from the stock's current price.
View analysts price targets for GSK or view top-rated stocks among Wall Street analysts.
How have GSK shares performed in 2023?: GSK's stock was trading at GBX 1,437.60 on January 1st, 2023. Since then, GSK shares have decreased by 0.5% and is now trading at GBX 1,430.60.
View the best growth stocks for 2023 here.
How were GSK's earnings last quarter?: GSK plc (LON:GSK) posted its quarterly earnings data on Wednesday, July, 29th. The company reported $56.90 earnings per share for the quarter. GSK had a trailing twelve-month return on equity of 61.26% and a net margin of 20.48%.

How often does GSK pay dividends? What is the dividend yield for GSK?: GSK announced a dividend on Wednesday, November 1st. Stockholders of record on Thursday, November 16th will be given a dividend of GBX 14 per share on Thursday, January 11th. This represents a dividend yield of 0.96%. The ex-dividend date is Thursday, November 16th. The official announcement can be viewed at this link.
Read our dividend analysis for GSK.
Is GSK a good dividend stock?: GSK (LON:GSK) pays an annual dividend of GBX 56 per share and currently has a dividend yield of 4.00%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 3,783.78%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for GSK.
What other stocks do shareholders of GSK own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN), General Electric (GE), Royal Dutch Shell (RDSB), Vodafone Group Public (VOD), Intel (INTC), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Barclays (BARC) and Gilead Sciences (GILD).
How do I buy shares of GSK?: Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:GSK) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

GSK Share Price, News & Analysis (LON:GSK)

GSK MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About GSK Stock (LON:GSK)

GSK Stock Price History

GSK Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

Should I Buy GSK Stock? GSK Pros and Cons Explained

Pros

Cons

GSK Stock Analysis - Frequently Asked Questions

Overall MarketRank^™